Combating the great mimicker: latest progress in the development of Burkholderia pseudomallei vaccines

References

• Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18:383–416.
   PubMed Web of Science ®Google Scholar
• Cheng AC, Dance DAB, Currie BJ. Bioterrorism, Glanders and melioidosis. Euro Surveill. 2005;10:11–12.
   PubMedGoogle Scholar
• Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012;367:1035–1044.
   PubMed Web of Science ®Google Scholar
• Limmathurotsakul D, Golding N, Dance DAB, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016;1:15008.
   Web of Science ®Google Scholar
• Currie BJ, Dance DAB, Cheng AC. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans R Soc Trop Med Hyg. 2008;102:S1–4.
   PubMed Web of Science ®Google Scholar
• Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, et al. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg. 2010;82:1113–1117.
   PubMed Web of Science ®Google Scholar
• Petersen H, Nieves W, Russell-Lodrigue K, et al. Evaluation of a Burkholderia pseudomallei outer membrane vesicle vaccine in nonhuman primates. Procedia Vaccinol. 2014;8:38–42.
   PubMedGoogle Scholar
• Wiersinga WJ, Virk HS, Torres AG, et al. Melioidosis. Nat Rev Dis Primers. 2018;4:17107.
   PubMed Web of Science ®Google Scholar
• Benoit TJ, Blaney DD, Gee JE, et al. Melioidosis cases and selected reports of occupational exposures to Burkholderia pseudomallei–United States, 2008-2013. MMWR Surveill Summ. 2015;64:1–9.
   PubMed Web of Science ®Google Scholar
• Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis. 2010;4:e900.
   PubMed Web of Science ®Google Scholar
• Titball RW, Burtnick MN, Bancroft GJ, et al. Burkholderia pseudomallei and Burkholderia mallei vaccines: are we close to clinical trials? Vaccine. 2017;35:5981–5989.
   PubMed Web of Science ®Google Scholar
• Currie BJ. Advances and remaining uncertainties in the epidemiology of Burkholderia pseudomallei and melioidosis. Trans R Soc Trop Med Hyg. 2008;102:225–227.
   PubMed Web of Science ®Google Scholar
• Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med. 2015;36:111–125.
   PubMed Web of Science ®Google Scholar
• Pumpuang A, Phunpang R, Ekchariyawat P, et al. Distinct classes and subclasses of antibodies to hemolysin co-regulated protein 1 and O-polysaccharide and correlation with clinical characteristics of melioidosis patients. Sci Rep. 2019;9:13972.
   PubMed Web of Science ®Google Scholar
• Jones AL, Beveridge TJ, Woods DE. Intracellular survival of Burkholderia pseudomallei. Infect Immun. 1996;64:782–790.
   PubMed Web of Science ®Google Scholar
• Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist Update. 2016;28:82–90.
   PubMed Web of Science ®Google Scholar
• Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection. Emerg Infect Dis. 2010 [2012];18:e2.
   Google Scholar
• Rotz LD, Khan AS, Lillibridge SR, et al. Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002;8:225–230.
   PubMed Web of Science ®Google Scholar
• Voskuhl GW, Cornea P, Bronze MS, et al. Other bacterial diseases as a potential consequence of bioterrorism: Q fever, brucellosis, glanders, and melioidosis. J Okla State Med Assoc. 2003;96:214–217.
   PubMedGoogle Scholar
• U.S. Department of Health and Human Services et al. 2018 Annual report of the federal select agent program. (2018) 1–28.
   Google Scholar
• Burtnick MN, Shaffer TL, Ross BN, et al. Development of subunit vaccines that provide high-level protection and sterilizing immunity against acute inhalational melioidosis. Infect Immun. pii 2018;86: e00724–17.
   PubMed Web of Science ®Google Scholar
• Limmathurotsakul D, Funnell SG, Torres AG, et al. Consensus on the development of vaccines against naturally acquired melioidosis. Emerg Infect Dis2015;21. DOI:10.3201/eid2106.141480.
   Google Scholar
• Morici L, Torres AG, Titball RW. Novel multi-component vaccine approaches for Burkholderia pseudomallei. Clin Exp Immunol. 2019;196:178–188. .
   PubMed Web of Science ®Google Scholar
• Leakey AK, Ulett GC, Hirst RG. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb Pathog. 1998;24:269–275.
   PubMed Web of Science ®Google Scholar
• Warawa J, Woods DE. Melioidosis vaccines. Expert Rev Vaccines. 2002;1:477–482.
   PubMedGoogle Scholar
• Nieves W, Petersen H, Judy BM, et al. A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol. 2014;21:747–754.
   PubMed Web of Science ®Google Scholar
• Khakhum N, Bharaj P, Myers JN, et al. Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis. PLoS Negl Trop Dis. 2019;13:e0007578.
   PubMed Web of Science ®Google Scholar
• Khakhum N, Bharaj P, Myers JN, et al. Burkholderia pseudomallei ΔtonB Δhcp1 live attenuated vaccine strain elicits full protective immunity against Aerosolized Melioidosis infection. mSphere. pii: 2019;4: e00570–18.
   PubMed Web of Science ®Google Scholar
• Amemiya K, Dankmeyer JL, Biryukov SS, et al. Deletion of two genes in Burkholderia pseudomallei MSHR668 that target essential amino acids protect acutely infected BALB/c mice and promote long term survival. Vaccines (Basel). pii: 2019;7: E196.
   PubMed Web of Science ®Google Scholar
• Muruato LA, Tapia D, Hatcher CL, et al. Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei. Clin Vaccine Immunol. pii: 2017;24: e00206–17.
   PubMedGoogle Scholar
• Wildaliz N, Asakrah S, Qazi O, et al. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine. 2011;29:8381–8389.
   PubMed Web of Science ®Google Scholar
• Muruato LA, Torres AG. Melioidosis: where do we stand in the development of an effective vaccine? Future Microbiol. 2016;11:477–480.
   PubMed Web of Science ®Google Scholar
• Kulp A, Kuehn MJ. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol. 2010;64:163–184.
   PubMed Web of Science ®Google Scholar
• Nieves W, Asakrah S, Qazi O, et al. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine. 2011;29:8381–8389.
   PubMed Web of Science ®Google Scholar
• Burtnick MN, Heiss C, Roberts RA, et al. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front Cell Infect Microbiol. 2012;2:108.
   PubMed Web of Science ®Google Scholar
• Gregory AE, Judy BM, Qazi O, et al. A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine. 2015;11:447–456.
   PubMed Web of Science ®Google Scholar
• Torres AG, Gregory AE, Hatcher CL, et al. Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. Vaccine. 2015;33:686–692.
   PubMed Web of Science ®Google Scholar
• Hatcher CL, Mott TM, Muruato LA, et al. Burkholderia mallei CLH001 attenuated vaccine strain is immunogenic and protects against Acute respiratory glanders. Infect Immun. 2016;84:2345–2354.
   PubMed Web of Science ®Google Scholar
• Noinaj N, Guillier M, Barnard TJ, et al. TonB-dependent transporters: regulation, structure, and function. Annu Rev Microbiol. 2010;64:43–60.
   PubMed Web of Science ®Google Scholar
• Duangurai T, Indrawattana N, Pumirat P. Burkholderia pseudomallei Adaptation for Survival in Stressful Conditions. Biomed Res Int. 2018;2018:3039106.
   PubMed Web of Science ®Google Scholar
• Park YJ, Lacourse KD, Cambillau C, et al. Structure of the type VI secretion system TssK–TssF–TssG baseplate subcomplex revealed by cryo-electron microscopy. Nat Commun. 2018;9:5385.
   PubMed Web of Science ®Google Scholar
• Burtnick MN, DeShazer D, Nair V, et al. Burkholderia mallei cluster 1 type VI secretion mutants exhibit growth and actin polymerization defects in RAW 264.7 murine macrophages. Infect Immun. 2010;78:88–99.
   PubMed Web of Science ®Google Scholar
• Burtnick MN, Brett PJ, Harding SV, et al. The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei.. Infect Immun. 2011;79:1512–1525.
   PubMed Web of Science ®Google Scholar
• Alifano P, Fani R, Liò P, et al. Histidine Biosynthetic pathway and genes: structure, regulation, and evolution. Microbiol Rev. 1996;60:44–69.
   PubMedGoogle Scholar
• Shanks J, Burtnick MN, Brett PJ, et al. Burkholderia mallei tssM encodes a putative deubiquitinase that is secreted and expressed inside infected RAW 264.7 murine macrophages. Infect Immun. 2009;77:1636–1648.
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013;9:2505–2523.
   PubMed Web of Science ®Google Scholar
• Scott AE, Burtnick MN, Stokes MG, et al. Burkholderia pseudomallei Capsular Polysaccharide conjugates provide protection against Acute Melioidosis. Infect Immun. 2014;82:320613.
   Web of Science ®Google Scholar
• Jenjaroen K, Chumseng S, Sumonwiriya M, et al. T-Cell responses are associated with survival in Acute Melioidosis Patients. PLoS Negl Trop Dis. 2015;9:e0004152.
   PubMed Web of Science ®Google Scholar
• Luangasanatip N, Flasche S, Dance DAB, et al. The global impact and cost-effectiveness of a melioidosis vaccine. BMC Med. 2019;17:1–11.
   PubMed Web of Science ®Google Scholar